Orlistat - lipid-lowering agent for the treatment of obesity.
The pharmacological properties of orlistat
The active ingredient of the drug blocks the intestine and the stomach enzymes that break down fats (lipase). Thus it becomes impossible to disintegration of complex fats into fatty acids and monoglycerides, and they are not absorbed from the gut and are output unchanged. The components of the digestion of fats are not absorbed into the blood when taking orlistat, that is in the body create a calorie deficit, which is why he begins to lose his own, in the form of deferred excess adipose tissue.
The received dose of the drug exerts its activity without causing systemic effects on the entire body. The therapeutic dose of orlistat blocks about 30% of the digestion of fats.
According to studies, the drug has no adverse effect on the composition and properties of bile on the speed of advance of the food bolus in the digestive tract or the acidity of gastric juice. The effect of increasing doses above the therapeutic was insignificant. Long-term use of orlistat (3 weeks or more) had a negligible effect on the balance of certain trace elements in the body (magnesium, calcium, zinc, copper, iron, phosphorus).
There is a clear link between obesity and the presence of cardiovascular disease, type 2 diabetes, gallstone disease, some forms of cancer. By reducing body weight in obese patients orlistat prevents the appearance of such states and mortality.
According to the observations, 24-48 hours after the start of treatment in the stool increased fat content. After the cancellation of orlistat fat in the stool reduced to normal within 2-3 days.
The drug is almost not absorbed from the digestive tract, it is converted in the body in small amounts in two inactive metabolites, but 83% of it is excreted in the feces in unmodified state. Orlistat is not carcinogenic, embryotoxic, mutagenic.
According to the instructions issued Orlistat capsules blue on 120 mg.
In conjunction with a low calorie diet orlistat under the instruction is used in order to reduce obesity and overweight. The drug is also suitable for reducing the likelihood of re-gain weight after the initial reduction. The values of body mass index regulate the appointment of orlistat for obesity with a BMI ≥30 kg / m2, and even when the figures BMI ≥27 kg / m2 and presence of risk factors (hypertension, diabetes, and others.).
Orlistat does not apply in case of hypersensitivity to the drug, with cholestasis (bile stasis) and chronic malabsorption in the small intestine (malabsorption).
Due to the lack of research on the safety and efficacy of the drug in children, lactating and pregnant women, its use is limited. Precautions should be taken in the presence of orlistat and calcium oxalate kidney stones, hyperoxaluria history.
Instructions for use of orlistat
According to the instructions the drug should be taken with food, not later than 1 hour after the meal. Dosage corresponds to 120 mg three times a day. By increasing the therapeutic dose of orlistat on responses to a certain level rise and its lipid-lowering effect. If for some reason it missed meal, or it lacks fats permitted skipping one dose.
In patients with concomitant diabetes while reducing weight while taking orlistat may require a dose reduction of glucose-lowering drugs.
Side effects of orlistat
Orlistat Review occasionally can cause a number of adverse reactions:
- The strong urge to defecate, its acceleration;
- Steatorrhea (increase of fat in the stool);
- Oily discharge from the rectum;
- Pain or discomfort in the abdomen;
- Allergic reactions.
If during treatment does not comply with low-calorie diet, the incidence of adverse reactions in the digestive tract increases.